Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia

Kentaro Ichioka, Hiroki Ohara, Naoki Terada, Yoshiyuki Matsui, Koji Yoshimura, Akito Terai, Yoichi Arai

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Background: The present study assessed the long-term efficacy (>12 months) of tamsulosin in 123 patients with lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). Methods: The patients received a starting dose of tamsulosin of 0.2 mg/day, with a further titration up to 0.4 mg/day until symptom relief. Subjective and objective clinical variables were assessed using the international prostate symptom score (IPSS), IPSS quality of life (QoL) score, BPH impact .index score, peak urinary flow rate (Qmax) and postvoid residual urine volume. Results: Except for Qmax, all clinical variables showed significant sustained improvements from baseline throughout the study period (median follow up, 43 months). Thirty patients (24.4%) withdrew because of surgical interventions. The Cox proportional hazards model showed that a baseline IPSS total score ≥15 (HR [hazard ratio] 2.13; 95% CI 1.04-4.34) was predictive of failure for tamsulosin therapy. Furthermore, during the first 12 months, a lowest IPSS total score ≥13 (HR 2.34; 95% CI 1.12-4.89), a lowest IPSS QoL score ≥3 (HR 4.16; 95% CI 1.26-13.68), and a lowest BPH impact index score ≥4 (HR 3.54; 95% CI 1.62-7.75) were also predictive of failure for tamsulosin therapy. Conclusions: Tamsulosin treatment of BPH patients for more than 12 months showed a sustained, stable efficacy. Patients without short-term effects were prone to withdraw from tamsulosin therapy, but so did patients with a high baseline IPSS total score, even if therapy was effective for at least 12 months.

Original languageEnglish
Pages (from-to)870-875
Number of pages6
JournalInternational Journal of Urology
Volume11
Issue number10
DOIs
Publication statusPublished - 2004 Oct

Keywords

  • Alpha-blockers
  • Long term
  • Symptomatic BPH
  • Tamsulosin

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this